There's no real new information in these links, but they show that the start of Phase 3 trofinetide in Rett syndrome has been noted on Rett-related sites, pharma industry sites and financial market industry sites.
Neuren is mentioned in most of the articles.
https://www.rettsyndrome.org/acadia-announces-launch-of-phase-3-lavender-study-for-trofinetide/
https://rettsyndromenews.com/2019/1...der-trial-in-u-s-to-further-test-trofinetide/
https://www.pharmaceutical-business...ivotal-study-of-trofinetide-in-rett-syndrome/
https://www.clinicaltrialsarena.com/news/acadia-trofinetide-rett-syndrome/
https://www.nasdaq.com/press-releas...-phase-3-pivotal-study-of-trofinetide-in-rett
https://www.streetinsider.com/Busin...pmental Congenital CNS Disorder/16066410.html
Ann: Phase 3 trial of trofinetide in Rett syndrome commences, page-47
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |